290 likes | 435 Views
Reducing the costs of medicine by dispensing generic medicine 25 September 2013. Presented by: Christo Rademan – Managing Director. Where does the data come from? Legislation regarding generic substitution Generic utilisation trends in Namibia
E N D
Reducing the costs of medicine by dispensing generic medicine 25 September 2013 Presented by: Christo Rademan – Managing Director
Where does the data come from? Legislation regarding generic substitution Generic utilisation trends in Namibia Factors that drive generic utilisation Measures to promote generic utilisation Contents
Mediscor PBM • Pharmaceutical Benefit Management Company • Experienced – was established in 1989 and has been in business for more than 24 years • An independent company with 119 staff members • 85 Clients: medical schemes, insurance products, sick funds, price files • More than 1.6 million lives • Namibia: 4 open & closed schemes
Legislation: Mandatory generic substitution • Medicines and Related substances control Act, 2003 (Act 13 of 2003) • Came into effect August 2008 • “A pharmacist must inform all members of the public of the benefits of substituting the requested medicine with an interchangeable multi-source medicine” • “And may dispense an interchangeable multi-source medicine instead of the medicine on the prescription”
Generic utilisation rate (2013) • Namibia 31-45% • RSA 53% • USA 70%+
Generic utilisation trends South Africa 73.2% 57.0% 53.4% 43.0% 26.8% 27.7% 19.8% 15.3%
Generic utilisation trends Namibia 61.9% 61.1% Legislation had no impact 47.5% 44.9%
Generic utilisation trends Namibia 61.9% 61.1% 47.5% 44.9% 38.1% 38.9% 16.2% 14.7%
Generic utilisation 2013 % Expenditure % Volume
Generic utilisation Per benefit category (2013)
Generic medicines as a source of affordable health care Originals - valid patent Originals - expired patent Generic equivalents Based on 2013 data
Cost per item – SA vs. Namibia R2.52 N$1.72 N$1.51 R1.39 N$1.00 R1.00
Current dispensing fee structure – SA vs. Namibia NB: Namibian fee structure rewards dispensing expensive products
SA maximum legislated dispensing fee Government Gazette, 19 November 2010
Impact of SA max legislated dispensing fee on Namibia Data: Namibian Medical Scheme
Factors that drive / influence generic utilisation • Availability of generic alternatives • Mandatory generic substitution • Prescriber and provider education / attitudes • Provider incentives • Procurement behaviour of providers • Consumer education • Funder rules / benefit design • Generic reference pricing • Formularies
Promoting generic utilisation - funders Active pharmacy management Engaging roll players to promote generic utilisation Provider engagement – actively monitor pharmacy performance • Applying management tools (Patient Experience Monitor) • Monitoring co-payments at the point of service • Engaging with pharmacy to change dispensing behaviour • Specifying acceptable, cost-effective products during chronic authorisation
Promoting generic utilisation - funders Member engagement – inform member of cost-effective generic alternatives • Promote high-performing pharmacies by area • Communicating these pharmacies via the authorization process • SMS messaging to members regarding co-payments • Communicating quarterly with pharmacies
Mediscor Pharmacy Management Objectives: • To actively work with Pharmacy to optimize dispensing behaviour • To reduce member co-payments, driving the concept of a ‘wallet-free’ experience • To drive generic substitution towards the use of Mediscor reference price (MRP) products • To drive members towards network pharmacies Ensures cost-effective delivery of benefits
Value of PEM – Optimizes the experience • Measures the ideal behaviour per line • That can be rolled up by Option, Pharmacy, Group, etc. • Very powerful • Enables meaningful engagement at Pharmacy level • Enables network contracting and management Provides the ability to form preferred partnerships
Conclusion • Generic utilisation decreased over the past 4 years • 16% of volume is from brands with patent expired • Multiple factors influence generic utilisation • Legislation had no impact! • Behaviour change needs to be driven by: • Rewards & incentives • Education • Provider engagement • Misalignment of provider and funder interests to be resolved
Thank you! Any Questions?